HD-OPM Archive
Topics › Statins

Statin use linked to slower cognitive decline in Alzheimer's and mixed dementia

Louis Nervegna · Dec 25, 2025 · ♥ 11 reactions · 2 comments · original Facebook post
StatinsBrain health & dementia
AI summary & key facts

Louis shares a registry-based cohort study associating statin use with slower decline, noting the ongoing PREVENTABLE trial should test this.

Statin use may slow cognitive decline in people with Alzheimers.

longevity.technologyStudy links cholesterol drugs to slower alzheimers declinelongevity.technology Paper · Alz Res Therapy · 2023Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort studyBackground Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. Objective To explore the association between the use of lipid-lowering medications and cognitive decline over time in a cohort of patients with AD or mixed…link.springer.com

This study was just published.

The overall evidence that statins may protect against Alzheimers is promising. We now have a huge 20,000 person randomized trial (PREVENTABLE) that is specifically testing statins as an intervention to protect against dementia in people over the age of 75yo: ↪ PREVENTABLE: atorvastatin 40 mg vs placebo up to 5 years in ~20,000 adults 75+. This trial is on-going and should report results in the next few years. To read past posts on this topic of statins and dementia, you can search the group for the tag #statinsdementiaHD.

Quoted:

A large registry-based study out of Sweden suggests that patients with Alzheimer’s dementia who take statins experience a gentler erosion of thinking ability than those who don’t. The work, published in Alzheimer Research and Therapy, comes from researchers at the Karolinska Institutet and draws on real-world records from the Swedish Registry for Cognitive/Dementia Disorders. It doesn’t prove causality – observational data rarely does – but in a field where disease-modifying wins are still scarce, even a credible signal matters [1].

The cohort was substantial: 15,586 patients diagnosed with Alzheimer’s disease or mixed dementia, all of whom had a clinical indication for lipid-lowering therapy. Nearly 11,000 received statins. The average age at diagnosis was 79.5 years, and roughly 60% were women.”

Quoted:

Cognitive change was tracked using the Mini-Mental State Examination (MMSE), the workhorse test for memory, attention, language and basic problem-solving. Over three years, statin users declined more slowly than non-users. The slope didn’t flatten completely – but it softened.

Patients on a standard daily statin dose scored, on average, 0.63 MMSE points higher after three years than those not taking statins. Modest. Measurable. The kind of effect that can disappear in underpowered trials, yet show up in big, messy registries that mirror real clinical life.

Quoted:

“People with Alzheimer’s dementia treated with statins had better cognitive development over time,” said Sara Garcia-Ptacek, lead author of the study.

At the same time, she stressed that the findings should not be interpreted as a blanket recommendation to start statins solely for dementia treatment.

“However, the results of the study do not mean that we now have evidence that people with dementia should be treated with statins. But on the other hand, we can’t see any support for not doing so. So, if a person needs statins for high blood lipids, a dementia diagnosis should not stop the treatment,” Garcia-Ptacek noted.

Garcia-Ptacek also pointed to why earlier clinical trials in this space have mostly come up empty. Many were small. Some were short. Subtle effects slip through the cracks. A registry-based approach, by contrast, can function like a wide-net signal detector – not proof, but a justification for designing a sharper, adequately powered study.

“The basic idea of this study was to pave the way for a more precise cohort study that could eventually lead to a clinical intervention study, which is what is needed to prove a causal link between statins and cognition,” she explained.

#statinsHD #statinsdementiaHD #simvastatinHD #dementiaHD #alzheimersHD

Research cited

Study links statin use to slower cognitive decline in Alzheimer’s patients, prompting renewed interest in repurposing common heart drugs.

#longevity #AlzheimersResearch #Statins #DrugRepurposing #Neurodegeneration #BrainHealth

📍 Follow us for more great content!

No photo description available.
← newer: PREVENTABLE: 20,000-person RCT testing atorvastatin to preveolder: Coffee compounds have antifibrotic and metabolic effects on →